AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02898506
Drug: Victoza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
Trial: NCT02898506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
Trial: NCT02336503
Drug: BBI-4000 Gel, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI-4000 Gel, 5%
Trial: NCT02336503
Drug: BBI-4000 Gel, 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI-4000 Gel, 10%
Trial: NCT02336503
Drug: BBI-4000 Gel, 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBI-4000 Gel, 15%
Trial: NCT02336503
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, BBI-4000 Gel, 0%
Trial: NCT01690247
Drug: Conventional plus UC-MSC
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Trial: NCT01690247
Drug: Conventional plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Trial: NCT00692016
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered under fasting condition
Trial: NCT00692016
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered under fed condition
Trial: NCT03117270
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo oral tablet q.d.
Trial: NCT03695835
Drug: Immunotherapeutic Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
Trial: NCT02229604
Drug: HRT, DHEA and herb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
Trial: NCT01015196
Drug: Zavedos
RxNorm normalized name: Zavedos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01786109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will match study drug; taken as one dose orally with water.
Trial: NCT00818844
Drug: Nepafenac 0.1%
RxNorm normalized name: NEPAFENAC 0.1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID
Trial: NCT00009893
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00009893
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00894647
Drug: placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
Trial: NCT01967875
Drug: Capecitabine+Cisplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
Trial: NCT01967875
Drug: Docetaxel+Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
Trial: NCT01281306
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
Trial: NCT01281306
Drug: AHU377
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
Trial: NCT01281306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as tablets in blister cards.
Trial: NCT00103506
Drug: Doxorubicin hydrochloride (DOXIL/CAELYX)
RxNorm normalized name: doxorubicin Injection [Caelyx]
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
Trial: NCT00538538
Drug: vitrectomy with subretinal lucentis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A gas bubble will be placed in the eye after the gel has been removed.
Trial: NCT00538538
Drug: vitrectomy with subretinal lucentis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
Trial: NCT03435744
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg added to TAU for 3 months.
Trial: NCT00890721
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the operation, 30cc of SKY0402 are injected into the wound.
Trial: NCT00890721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the hemorrhoidectomy, 30cc Placebo injected into the wound.
Trial: NCT01030575
Drug: Inositol lower volume
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
Trial: NCT01030575
Drug: Inositol mid-level volume
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
Trial: NCT01030575
Drug: Inositol high volume
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
Trial: NCT01030575
Drug: Placebo low volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 5% given in volumes equal to that of the comparator drug
Trial: NCT03880409
Drug: 2% lidocaine with 1:000,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
Trial: NCT03880409
Drug: 4% articaine with 1:000,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with 1:000,000 epinephrine is dental local anesthesia
Trial: NCT02384460
Drug: SD-101-6.0 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied topically once a day for 90 days
Trial: NCT02384460
Drug: Placebo (SD-101-0.0) cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied topically once a day for 90 days
Trial: NCT00373711
Drug: F-18 FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 mCi, iv
Trial: NCT00815737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of Placebo
Trial: NCT01830699
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cc (40 mg/mL) triamcinolone intra-bursal once
Trial: NCT03110276
Drug: EYP001a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
Trial: NCT03110276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
Trial: NCT00556959
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets for 8 weeks
Trial: NCT02421510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, once daily, before the first meal of the day
Trial: NCT01843881
Drug: Exendin 9, 39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
Trial: NCT01843881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A saline infusion will be given to match the study drug infusion.
Trial: NCT01294540
Drug: Drug: E2609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2609 orally at varying ascending doses
Trial: NCT01294540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT01311661
Drug: Placebo twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Placebo of Olodaterol twice daily
Trial: NCT01806792
Drug: risedronate combine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01806792
Drug: Placebo(for Risedronate)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01806792
Drug: Placebo(for risedronate combine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01972828
Drug: FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
Trial: NCT01972828
Drug: STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
Trial: NCT02094235
Drug: E6005 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02094235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g placebo ointment
Trial: NCT02094235
Drug: E6005 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02953054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching patches that have no active drug applied before surgery and worn for 72 hours.
Trial: NCT01873885
Drug: Placebo Single IV (Intravenous) Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride - 30 minute IV infusion
Trial: NCT00629239
Drug: AZD4818
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Powder, inhalation, b.i.d., 4 weeks
Trial: NCT00629239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00242476
Drug: MK0822A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03044561
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally, 4 times per day for 21 days
Trial: NCT01260753
Drug: UR-63325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UR-63325
Trial: NCT01260753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to UR 63325 and fluticasone propionate nasal spray
Trial: NCT00186797
Drug: Fludarabine, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02661971
Drug: Calciumfolinat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 200 mg/m², d1
Trial: NCT01937338
Drug: AZD7624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser solution; 20 mg/mL for inhalation
Trial: NCT01937338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebuliser solution for inhalation
Trial: NCT01084720
Drug: V0034 CR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01542099
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml.
Trial: NCT01542099
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml.
Trial: NCT01851512
Drug: T-R (Test-Reference drug)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01851512
Drug: R-T (Reference-Test drug)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877954
Drug: Extra-fine hydrofluoroalkane beclometasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01651598
Drug: Placebo to BI 144807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose (bid)
Trial: NCT02273453
Drug: Songha® Night
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02273453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02337946
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Trial: NCT02337946
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01873833
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01873833
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01449487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for administration in the rectum Identical tp active solution but without active drug
Trial: NCT02068599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Trial: NCT02286830
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
Trial: NCT00291915
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01106950
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
Trial: NCT00448149
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
Trial: NCT03346317
Drug: estradiol valerate tablets+dydrogesterone tablets
RxNorm normalized name: dydrogesterone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral estradiol valerate tablets+dydrogesterone tablets
Trial: NCT01870037
Drug: Placebo (PBS-20% sucrose)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01870037
Drug: hMaxi-K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
Trial: NCT03336866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT03336866
Drug: IXT-m200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXT-m200 is an anti-methamphetamine monoclonal antibody
Trial: NCT02049879
Drug: Corticosteroids injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
Trial: NCT03402087
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03402087
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT03923842
Drug: Chemotherapy as clinical standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
Trial: NCT00541775
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
Trial: NCT04518410
Drug: Placebo for BRII-196+BRII-198
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for SNG001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
Trial: NCT02478788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills with no medication in it
Trial: NCT02084342
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml, IV for 30min,before incision.
Trial: NCT00669344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
Trial: NCT00002874
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
Trial: NCT04113993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically packaged placebo capsule daily
Trial: NCT01980888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match idelalisib administered orally twice daily
Trial: NCT03018938
Drug: Insulin Analog Mid Mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03018938
Drug: Basal Insulin Analog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04230070
Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioequivalence
Trial: NCT04230070
Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioequivalence
Trial: NCT04441398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
Trial: NCT03679884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo film-coated tablets
Trial: NCT00723242
Drug: Viraferon-peg and Rebetol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00494156
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01408498
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
Trial: NCT00504309
Drug: 4/day of 4g P-OM3 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4/day of 4g P-OM3 capsules for 8 weeks
Trial: NCT00504309
Drug: 4/day of 1g P-OM3 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4/day of 1g P-OM3 capsules for 8 weeks
Trial: NCT01647685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution (same solution brand as used to dilute/prepare Nanocort injection)